

BEST AVAILABLE COPY

Jan Delaval please

Access DB# 70467

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: SABHA QAZI Examiner #: 74141 Date: 7/9/02
Art Unit: 1616 Phone Number 305-3910 Serial Number: 09/64,327
Mail Box and Bldg/Room Location: 2019, CM1 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Anti Angiogenic Agents
Inventors (please provide full names): AGOSTON, et al.

Earliest Priority Filing Date: 8/18/2000

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for the method of the
comps of formula in cl 10.

Elected sp. is compd of cl. 17.

Please start the search when $Z = CH_2$

Please see attached sheets

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>4498</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>✓</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>7/10/02</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>7/10/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>100</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+ 100</u>	Other _____	Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:22:58 ON 10 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4
DICTIONARY FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot l54

L54 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431902-08-8 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-ethyl-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 2 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431902-07-7 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-[(dimethylamino)methyl]-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H33 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 3 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431902-06-6** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-(2-methylpropyl)-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H34 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 4 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431902-05-5** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H34 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 5 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431902-04-4 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H32 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 6 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431902-03-3 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-,
(16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H32 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 7 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431902-02-2** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 8 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431902-01-1** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-,
(16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 9 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431902-00-0** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-ethyl-2-methoxy-, (17.beta.)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 10 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN **431901-99-4** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 11 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431901-98-3 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 12 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 431901-87-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H34 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:6309

L54 ANSWER 13 OF 18 REGISTRY COPYRIGHT 2002 ACS

RN 258278-72-7 REGISTRY

CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-16,16-dimethyl-,
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN EM 1926


FS STEREOSEARCH

MF C21 H27 N O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L54 ANSWER 14 OF 18 REGISTRY COPYRIGHT 2002 ACS

RN 257953-56-3 REGISTRY

CN Estra-1,3,5(10)-triene-2-carbonitrile, 3-hydroxy-17-oxo-16-(phenylmethyl)-,
(16.alpha.)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C26 H27 N O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L54 ANSWER 15 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 202397-97-5 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-2-methoxy-,
(16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H25 F O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:138115

L54 ANSWER 16 OF 18 REGISTRY COPYRIGHT 2002 ACS
RN 202397-93-1 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H25 F O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:138115

L54 ANSWER 17 OF 18 REGISTRY COPYRIGHT 2002 ACS

RN 54502-31-7 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 16-chloro-3-hydroxy-2-methoxy-, (16.beta.)-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 16.beta.-Chloro-3-hydroxy-2-methoxyestra-1,3,5(10)-trien-17-one


FS STEREOSEARCH

MF C19 H23 Cl O3

LC STN Files: BEILSTEIN*, CA, CAPLUS

(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 82:43650

L54 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2002 ACS

RN 54502-29-3 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 16-chloro-3-hydroxy-2-methoxy-, (16.alpha.)-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 16.alpha.-Chloro-3-hydroxy-2-methoxyestra-1,3,5(10)-trien-17-one


FS STEREOSEARCH

MF C19 H23 Cl O3

LC STN Files: BEILSTEIN*, CA, CAPLUS

(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 82:43650

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:23:08 ON 10 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2002 VOL 137 ISS 2
FILE LAST UPDATED: 9 Jul 2002 (20020709/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all hitstr tot 153

L53 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:488275 HCAPLUS
TI Antiangiogenic agents
IN Agoston, Gregory E.; Shah, Jamshed H.; Hunsucker, Kimberly A.; Pribluda, Victor S.; Lavalley, Theresa M.; Green, Shawn J.; Herbstritt, Christopher J.; Zhan, Xiaoguo H.; Treston, Anthony M.
PA USA
SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U. S. Ser. No. 933,894.

CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C07J041-00
 ICS C07J043-00; C07J001-00; A61K031-704; A61K031-58; A61K031-56;
 C07C247-00; A61K031-655; C07J009-00
 NCL 552544000
 CC 32 (Steroids)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082433	A1	20020627	US 2001-939208	20010824 <--
PRAI	US 2000-641327	A2	20000818	<--	
	US 2000-253385P	P	20001127		
	US 2000-255302P	P	20001213		
	US 2001-278250P	P	20010323		
	US 2001-933894	A2	20010821		

AB Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

L53 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:408687 HCAPLUS

DN 137:6309

TI Preparation of 2-methoxyestradiol analogs as antiangiogenic agents

IN Agoston, Gregory; Shah, Jamshed H.; Hunsucker, Kimberly A.; Pribluda, Victor; Lavalley, Theresa M.; Green, Shawn J.; Herbstritt, Christopher J.; Zhan, Xiaoguo H.; Treston, Anthony

PA Entremed, Inc., USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07J001-00

CC 32-3 (Steroids)



Section cross-reference(s): 1, 2, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042319	A2	20020530	WO 2001-US26490	20010824
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-253385P	P	20001127		
	US 2000-255302P	P	20001213		
	US 2001-278250P	P	20010323		
	US 2001-933894	A	20010821		

OS MARPAT 137:6309


GI



- AB 2-Methoxyestradiol analogs, such as I [R1, R3 = H, halo, CN, alkyl, OH, CH2OH, NH2, alkylamino; R2 = N3, CN, C.tplbond.CR, C=CHR, C.tplbond.CH, OR, amino; R = H, alkyl; Z = COH, COAc; dashed bond = single bond or double bond; R6 = H, OH, O, oxime, amino, alkyl, alkenyl; R4, R5 = H, alkyl, alkenyl, alkynyl], were prepd. for treating mammalian disease characterized by undesirable angiogenesis. Thus, 2-methoxyestradiol analog II was prepd. by the reaction of methyltriphenylphosphonium bromide and 2-methoxyestrone. In vitro evaluation against MDA-MB-231 breast tumor cells and HUVEC endothelial cells, II showed IC50 0.24.+-.0 and 0.19.+-.0.19 resp.
- ST methoxyestradiol deriv prepn antiangiogenic antitumor; estradiol methoxy deriv prepn antiangiogenic antitumor
- IT Cell proliferation
(inhibition; prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT Antitumor agents
(mammary gland; prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT Mammary gland
(neoplasm, inhibitors; prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT Angiogenesis inhibitors
Human
(prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT Estrogens
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT 53-63-4P, Estra-1,3,5(10)-trien-3-ol 431901-72-3P 431901-73-4P
431901-75-6P 431901-77-8P 431901-83-6P 431901-89-2P 431901-91-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT 1818-12-8P 4953-96-2P 6298-51-7P 6301-87-7P 6599-97-9P
7291-57-8P 10332-20-4P 32162-96-2P 41259-43-2P 94440-60-5P
165619-07-8P 165881-61-8P 192062-02-5P 229486-18-4P 431901-68-7P
431901-69-8P 431901-70-1P 431901-71-2P 431901-74-5P 431901-76-7P
431901-78-9P 431901-82-5P 431901-84-7P 431901-86-9P
431901-87-0P 431901-88-1P 431901-92-7P 431901-93-8P
431901-94-9P 431901-95-0P 431901-96-1P 431901-97-2P
431901-98-3P 431901-99-4P 431902-00-0P
431902-01-1P 431902-02-2P 431902-03-3P
431902-04-4P 431902-05-5P 431902-06-6P
431902-07-7P 431902-08-8P 431902-09-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


- (prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT 53-16-7, Estrone, reactions 64-18-6, Formic acid, reactions 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions 362-07-2, 2-Methoxyestradiol 1530-32-1, Ethyl triphenylphosphonium bromide 1779-49-3, Methyl triphenylphosphonium bromide 1779-51-7, Butyl triphenylphosphonium bromide 4784-77-4, Crotyl bromide 5815-08-7, tert-Butoxy bis(dimethylamino)methane 6228-47-3, Propyl triphenylphosphonium bromide 17640-15-2, Methyl cyanoformate
- RL: RCT (Reactant); RACT (Reactant or reagent)
- (prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT 26356-54-7P 26357-07-3P 93949-26-9P 431901-79-0P 431901-80-3P 431901-81-4P 431901-85-8P 431901-90-5P
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- IT 431901-87-0P 431901-98-3P 431901-99-4P 431902-00-0P 431902-01-1P 431902-02-2P 431902-03-3P 431902-04-4P 431902-05-5P 431902-06-6P 431902-07-7P 431902-08-8P
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (prepn. of 2-methoxyestradiol derivs. as antiangiogenic agents)
- RN 431901-87-0 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- RN 431901-98-3 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 431901-99-4 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-00-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-ethyl-2-methoxy-, (17.beta.)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 431902-01-1 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-02-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-03-3 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-04-4 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-05-5 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-06-6 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-(2-methylpropyl)-,
(16.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-07-7 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-[(dimethylamino)methyl]-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431902-08-8 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 16-ethyl-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L53 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
 AN 2000:116882 HCAPLUS
 DN 132:152024
 TI Preparation of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
 IN Labrie, Fernand; Merand, Yves; Gauthier, Sylvain; Provencher, Louis; Luu-The, Van
 PA Endorecherche, Inc., Can.
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 32-3 (Steroids)
 Section cross-reference(s): 1, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007576	A2	20000217	WO 1999-CA724	19990806
	WO 2000007576	A3	20000330		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9951449	A1	20000228	AU 1999-51449	19990806
	EP 1102582	A2	20010530	EP 1999-936218	19990806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	NO 2001000651	A	20010405	NO 2001-651	20010207
PRAI	US 1998-95623P	P	19980807		
	WO 1999-CA724	W	19990806		
OS	MARPAT 132:152024				
GI					



AB Novel methods of treating and/or inhibiting development of prostatic cancer, benign prostatic hyperplasia, prostatitis, acne, seborrhea, hirsutism or androgenic alopecia utilize inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase alone or in combination with other active pharmaceuticals such as inhibitors of type 5 17.beta.-hydroxysteroid dehydrogenase. The inhibitors, of formula I [R1 = OH, acyloxy, alkoxy, amido, etc.; R2, R4 = H, CN, F, Cl, Br, NO2; R3 = alkoxy, acyloxy, alkoxycarbonyloxy, OH, carbamate; R5 = H, alkyl, etc.; R1R5 = O, lactone ring; R6, R7 = H, alkyl, benzyl; R6R7 = cycloalkene], are prepd. Thus, II showed 98% inhibition of the transformation of 4-dione by type 3 3.alpha.-HSD. Pharmaceutical compns. contg. I are described.

ST hydroxysteroid dehydrogenase inhibitor steroid prepn

IT Prostate gland

(benign hyperplasia, treatment; prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT Steroids, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT Prostate gland

(prostatitis, treatment; prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT Acne

Alopecia
Hirsutism
Neoplasm
Seborrhea

(treatment; prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 243638-19-9P 243638-38-2P 243638-40-6P 243638-41-7P 243836-42-2P
257953-50-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 50-28-2P, Estradiol, preparation 1630-83-7P 16205-32-6P 93947-11-6P
93995-38-1P 243638-03-1P, EM 01667C 243638-98-4P, EM 01645
243640-08-6P 243640-10-0P 243836-37-5P 243836-40-0P, EM 1125
243841-16-9P 243841-55-6P 243841-61-4P 257953-48-3P 257953-49-4P
257953-51-8P 257953-52-9P 257953-53-0P 257953-54-1P 257953-55-2P
257953-56-3P 258278-38-5P, EM 1834 258278-49-8P, EM 1836
258278-72-7P, EM 1926 258278-74-9P, EM 2132 258278-77-2P, EM
2318 258278-78-3P, EM 2330 258278-79-4P, EM 2359

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 9028-56-2, 3.alpha.-Hydroxy steroid dehydrogenase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 257953-61-0P 257953-62-1P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 53-16-7, Estrone, reactions 521-18-6, Dihydrotestosterone 1624-62-0
6921-34-2, Benzylmagnesium chloride 40365-61-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 3262-23-5P 5976-73-8P, 2-Nitroestrone 54793-02-1P 57711-40-7P
58701-44-3P 165619-18-1P 225245-08-9P 225245-12-5P 243637-93-6P
243637-94-7P 243637-95-8P 243637-96-9P 243637-97-0P 243637-98-1P
243637-99-2P 243638-00-8P 243638-01-9P 243638-02-0P 243638-17-7P
243638-18-8P 243638-22-4P 257953-57-4P 257953-58-5P 257953-59-6P
257953-60-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 5976-74-9P, 4-Nitroestrone

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

IT 257953-56-3P 258278-72-7P, EM 1926


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase)

RN 257953-56-3 HCAPLUS

CN Estra-1,3,5(10)-triene-2-carbonitrile, 3-hydroxy-17-oxo-16-(phenylmethyl)-, (16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258278-72-7 HCAPLUS

CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-16,16-dimethyl-, (17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS

AN 1997:805513 HCAPLUS

DN 128:138115

TI The metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting the oxidative biotransformations of an estrogen-receptor imaging agent

AU Stalford, Anne C.; Maggs, James L.; Gilchrist, Thomas L.; Park, B. Kevin

CS Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, L69 3BX, UK

SO Steroids (1997), 62(12), 750-761

CODEN: STEDAM; ISSN: 0039-128X

PB Elsevier Science Inc.

DT Journal

LA English

CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 32

AB 16.alpha.-Fluoro-17.beta.-, 16.alpha.-fluoro-17.alpha.-, and 16.beta.-fluoro-17.beta.-[6,7-3H]estradiol were prepd. from [6,7-3H]estrone via fluorination of 3,17-bis(tert-butyldimethylsilyloxy)-[6,7-3H]estratetraene with N-fluoropyridinium triflate and redn. of 16.alpha.-.beta.-fluoro[6,7-3H]estrone with NaBH₄. The three isomers were sepd. by silica-phase high-performance liq. chromatog. They were administered i.v. (4 .mu.mol/kg) to anesthetized male rats. Their biliary metabolites (90-97% of dose over 6 h) were characterized by high performance liq. chromatog.-mass spectrometry and compared with those of [6,7-3H]17.beta.-estradiol. The four estrogens and their hydroxylated and methoxylated metabolites were excreted as glucuronides. C-16 fluorination blocked C-16 hydroxylation and also the dehydrogenation of the C-17 hydroxyl group. The 16.alpha.-17.beta. isomer was extensively glucuronylated at C(O)3 but also underwent arom. hydroxylation and methoxylation before conjugation. Its C-17 epimer was subject to much greater arom. hydroxylation but the catecholestrogen was O-methylated to a greater relative extent. The 16.beta.-17.beta. deriv. underwent alicyclic as well as substantial arom. hydroxylation and yielded numerous isomeric glucuronides of O-methylated catechols. Thus, the fluorine exerted complex effects (inhibitory and enhancing) on both localized (D-ring) and distal (A-ring) biotransformations of the estradiol mol.; the direction and magnitude of the effects being dependent upon the stereochem. at C-16 and C-17. These findings provide structural guidelines for restricting the metab. of tumor-imaging fluoroestrogens and thereby enhancing their delivery to the target tissue.

ST fluoroestradiol prepn metab estrogen receptor imaging

IT Drug metabolism

Imaging agents


Structure-activity relationship

Substituent effects

(metab. of 16-fluoroestradiols in vivo: chem. strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)


- IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- IT 84693-92-5P 92817-10-2P 92817-11-3P 202397-89-5P 202397-90-8P
202397-91-9P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN
(Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC
(Process)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- IT 202397-92-0 202397-93-1 202397-94-2 202397-95-3
202397-96-4 202397-97-5 202397-98-6 202397-99-7
202398-00-3 202398-01-4 202398-02-5 202398-03-6 202398-04-7
202398-05-8 202398-06-9 202398-07-0 202398-08-1 202398-09-2
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL
(Biological study); FORM (Formation, nonpreparative)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- IT 53-16-7, Estrone, reactions 3459-26-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- IT 130409-74-4P 130409-84-6P 202397-83-9P 202397-84-0P 202397-85-1P
202397-86-2P 202397-87-3P 202397-88-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- IT 202397-93-1 202397-97-5
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL
(Biological study); FORM (Formation, nonpreparative)
(metab. of 16-fluoroestradiols in vivo: chem. strategies for
restricting oxidative biotransformations of estrogen-receptor imaging
agent)
- RN 202397-93-1 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-2-methoxy-,
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- RN 202397-97-5 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-2-methoxy-,
(16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
 AN 1975:43650 HCAPLUS
 DN 82:43650
 TI Analytical chemical studies on steroids. LXXIII. Syntheses of epimeric
 2-hydroxy-16-chlorestrone monomethyl ethers
 AU Nambara, Toshio; Nokubo, Munetaka
 CS Pharm. Inst., Tohoku Univ., Sendai, Japan
 SO Chem. Pharm. Bull. (1974), 22(10), 2455-7
 CODEN: CPBTAL
 DT Journal
 LA English
 CC 32-6 (Steroids)
 GI For diagram(s), see printed CA Issue.
 AB Chloroestrone I (R = H, Me; R1 = H, Me; R2 = H, Cl, R3 = H, Cl) were
 prepd. from enol acetate II (R = Me, R1 = PhCH2; R = PhCH2, R1 = Me).
 Chlorination of II (R = Me, R1 = PhCH2) followed by debenzylation gave I
 (R = Me, R1 = R3 = H, R2 = Cl). Epimerization of I (R = Me, R1 = PhCH2,
 R2 = Cl, R3 = H) over alumina and subsequent debenzylation gave I (R = Me,
 R1 = R2 = H, R3 = Cl). Similarly, II (R = PhCH2, R1 = Me) gave I (R = H,
 R1 = Me, R2 = Cl, R3 = H and R = H, R1 = Me, R2 = H, R3 = Cl).
 ST chloroestrone epimerization; estratrienone chloro epimerization;
 chlorination estrone enol acetate
 IT 19-Norsteroids
 RL: RCT (Reactant)
 (16-chloro-17-oxo-1,3,5(10)-unsatd.)
 IT 51477-81-7 51477-94-2
 RL: RCT (Reactant)
 (chlorination of)
 IT 54502-30-6P 54502-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and debenzylation of)
 IT 54502-32-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and epimerization of)
 IT 54502-28-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and hydrogenolysis of)
 IT 54502-29-3P 54502-31-7P 54502-33-9P 54502-34-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 IT 54502-29-3P 54502-31-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 54502-29-3 HCAPLUS
 CN Estr-1,3,5(10)-trien-17-one, 16-chloro-3-hydroxy-2-methoxy-, (16.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54502-31-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 16-chloro-3-hydroxy-2-methoxy-, (16.beta.)-(9CI) (CA INDEX NAME).

Absolute stereochemistry.



=>

=>

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:23:28 ON 10 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

DICTIONARY FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 129


L18 STR



CH₂—OH
@21 22

NH—Ak
@23 24

Ak—OH
@29 30



Ak—N—Ak
27 @26 25

Cb—OH
@31 32

Ak—Cb—OH
@35 33 34

Cb—Ak—OH
@38 36 37

C—O
@39 40

C=N—O—G3
@46 47 48 49

Ak—Cb
@50 @51

CH—CN
@52 53

CH—NH₂
@54 55

CH—NH—G4
@56 57 58

VAR G1=H/X/CN/AK/OH/21/NH2/23/26
VAR G2=H/OH/29/31/35/38
VAR G3=H/AK/CB/50/51
VAR G4=AK/CB/50/51
VAR G6=CH2/39/46/52/54/56/59

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 2

CONNECT IS M1 RC AT 15

CONNECT IS M1 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 57

STEREO ATTRIBUTES: NONE

L20 4604 SEA FILE=REGISTRY CSS FUL L18

L21 STR

C~O
@39 40


C=N—O—G3
@46 47 48 49

Ak—Cb
@50 @51

CH—NH2
@54 55

CH—NH—G4
@56 57 58

CH—N—G4
@59 | 61
G4
63




67
O
||
CH—C—G4
@64 65 66

71
OH
|
C—G4
@69 70

VAR G3=H/AK/CB/50/51
VAR G4=AK/CB/50/51
VAR G5=CH2/39/46/54/56/59/69/64
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 1
CONNECT IS M1 RC AT 2
CONNECT IS M1 RC AT 3
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 7
CONNECT IS M1 RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L23 2114 SEA FILE=REGISTRY SUB=L20 CSS FUL L21
L24 STR



VAR G1=73/CN/76/79/82/85/91/95/NH2/96/60/CHO/64/98/100/102/104/108/111

VAR G2=OH/NH2/X/CF3

VAR G3=AK/CB/50/51/102/104/108/111

VAR G4=AK/CB/50/51

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 1

CONNECT IS M1 RC AT 3

CONNECT IS M1 RC AT 4

CONNECT IS M1 RC AT 7

CONNECT IS M1 RC AT 15

CONNECT IS M1 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 1

NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE

L26 170 SEA FILE=REGISTRY SUB=L23 CSS FUL L24

L27 STR



```

VAR G1=H/C/X/CY
VAR G2=C/X/CY
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 1
CONNECT IS M1 RC AT 2
CONNECT IS M1 RC AT 3
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 7
CONNECT IS M1 RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

```

```

STEREO ATTRIBUTES: NONE
L29          18 SEA FILE=REGISTRY SUB=L26 SSS FUL L27

```

```

100.0% PROCESSED      170 ITERATIONS
SEARCH TIME: 00.00.02

```

18 ANSWERS

=> d his

```

(FILE 'HOME' ENTERED AT 06:52:32 ON 10 JUL 2002)
SET COST OFF

```

FILE 'HCAPLUS' ENTERED AT 06:52:44 ON 10 JUL 2002

```

      E WO2001-US26128/AP, PRN
      E US2000-641327/AP, PRN
L1      1 S E4
      E AGOSTON G/AU
L2      21 S E5, E9, E10
      E PRILUDA V/AU
      E PRIBLUDA V/AU
L3      23 S E3-E7
      E TRESTON A/AU
L4      49 S E3-E8
      E GREEN S/AU
L5      185 S E3, E15, E16
      E GREEN SHAWN/AU
L6      54 S E3-E5
      E ENTREMED/PA, CS
L7      64 S E3-E15
L8      3 S L2-L7 AND STEROID?/SC, SX
L9      3 S L2-L7 AND STEROID?/CW
      E STEROID/CT
      E E70+ALL
L10     25 S L2-L7 AND E2+NT
L11     6 S L8, L9
L12     5 S L10 AND L11
L13     6 S L11, L12
L14     6 S L1, L13
L15     20 S L10 NOT L14
L16     35 S L2-L7 AND ?ANGIOG?
L17     2 S L16 AND L8-L15

```

FILE 'REGISTRY' ENTERED AT 06:58:02 ON 10 JUL 2002

```

L18      STR
L19     50 S L18 CSS SAM

```

L20 4604 S L18 CSS FUL
SAV L20 QAZI641/A
L21 STR L18
L22 50 S L21 CSS SAM SUB=L20
L23 2114 S L21 CSS FUL SUB=L20
SAV L23 QAZI641A/A
L24 STR L21
L25 6 S L24 CSS SAM SUB=L23
L26 170 S L24 CSS FUL SUB=L23
SAV L26 QAZI641B/A
L27 STR L18
L28 2 S L27 SAM SUB=L26
L29 18 S L27 FUL SUB=L26
SAV L29 QAZI641C/A
L30 152 S L26 NOT L29

FILE 'HCAOLD' ENTERED AT 07:49:17 ON 10 JUL 2002

L31 0 S L29

FILE 'USPATFULL, USPAT2' ENTERED AT 07:49:21 ON 10 JUL 2002

L32 1 S L29

FILE 'HCAPLUS' ENTERED AT 07:49:56 ON 10 JUL 2002

L33 4 S L29
L34 1 S L33 AND L1-L7
L35 9 S L20 AND L1-L7
L36 1 S L35 AND L34
SEL RN

FILE 'REGISTRY' ENTERED AT 07:51:31 ON 10 JUL 2002

L37 72 S E1-E72
L38 62 S L37 AND C5-C6-C6-C6/ES
L39 49 S L38 AND L20
L40 13 S L38 NOT L39
L41 39 S L39 AND L23
L42 10 S L39 NOT L41
L43 31 S L41 AND L26
L44 8 S L41 NOT L43
L45 12 S L43 AND L29
L46 19 S L43 NOT L45
SAV L47 QAZI641D/A
DEL QAZI641D/A
L47 STR L27
L48 38 S L47 CSS FUL SUB=L26
SAV L48 QAZI641D/A
L49 20 S L48 NOT L29

FILE 'HCAPLUS' ENTERED AT 08:19:06 ON 10 JUL 2002

L50 4 S L33, L34
L51 5 S L1, L50
L52 5 S L51 AND L1-L17, L50, L51

FILE 'HCAPLUS' ENTERED AT 08:20:24 ON 10 JUL 2002

FILE 'REGISTRY' ENTERED AT 08:21:05 ON 10 JUL 2002

FILE 'HCAPLUS' ENTERED AT 08:22:10 ON 10 JUL 2002

L53 5 S L1, L33
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 08:22:43 ON 10 JUL 2002

L54 18 S E73-E90

← false hit

FILE 'REGISTRY' ENTERED AT 08:22:58 ON 10 JUL 2002

FILE 'HCAPLUS' ENTERED AT 08:23:08 ON 10 JUL 2002

FILE 'REGISTRY' ENTERED AT 08:23:28 ON 10 JUL 2002

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 08:24:19 ON 10 JUL 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 08:24:19 ON 10 JUL 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d trial 132

L32 ANSWER 1 OF 1 USPATFULL

AN 1999:143299 USPATFULL

TI Selective denial of encrypted high precision data by indirect keying

INCL INCLM: 380/021.000

INCLS: 380/009.000; 342/354.000; 342/357.000

NCL NCLM: 380/258.000

NCLS: 342/354.000; 342/357.150; 380/278.000

IC [6]

ICM: H04L009-00

ICS: H04B007-185; G01S005-02; H04K001-02

GI	SECTION	PAGES	FORMAT	SIZE
	FRONT PAGE	1	PAGE.FP	43K
	DRAWINGS	2-4	PAGE.DRAW	49K
	DESCRIPTION	5-8	PAGE.DESC	532K
	CLAIMS	8-10	PAGE.CLM	302K
	COMPLETE	1-10	PAGE.ALL	795K

Use PAGE(n) to retrieve a specific page

=> d hit 132

L32 ANSWER 1 OF 1 USPATFULL

IT 50-28-2P, Estradiol, preparation 1630-83-7P 16205-32-6P 93947-11-6P
 93995-38-1P 243638-03-1P, EM 01667C 243638-98-4P, EM 01645
 243640-08-6P 243640-10-0P 243836-37-5P 243836-40-0P, EM 1125
 243841-16-9P 243841-55-6P 243841-61-4P 257953-48-3P 257953-49-4P
 257953-51-8P 257953-52-9P 257953-53-0P 257953-54-1P 257953-55-2P
257953-56-3P 258278-38-5P, EM 1834 258278-49-8P, EM 1836
258278-72-7P, EM 1926 258278-74-9P, EM 2132 258278-77-2P, EM
 2318 258278-78-3P, EM 2330 258278-79-4P, EM 2359
 (prepn. of steroids as inhibitors of type 3 3.alpha.-hydroxysteroid
 dehydrogenase)